Recursion Pharmaceuticals Inc is a trailblazer in the biotech industry, focusing on revolutionizing drug discovery by merging advancements in biology, chemistry, automation, data science, and engineering. With a robust pipeline of drugs in various clinical trial stages, including treatments for cerebral cavernous malformation, neurofibromatosis type 2, familial adenomatous polyposis, Clostridioides difficile infection, and certain cancers, Recursion is at the forefront of developing innovative therapies. Founded in 2013 and based in Salt Lake City, Utah, the company collaborates with leading entities like Bayer AG and Takeda Pharmaceutical to push the boundaries of medical research.
Anthropic is racing toward a public debut in September with a healthcare AI pitch that could ignite a sector most investors are not watching. Five biotech names are already moving, and one…
Artificial intelligence is reshaping nearly every industry, but some of its biggest opportunities are emerging far from Silicon Valley. Biotechnology has spent decades producing breakthrough medicines, yet drug development has remained painfully…
SPDR S&P Biotech ETF (NYSEARCA:XBI) is built around a deceptively simple idea: give every biotech company roughly equal footing, regardless of size. That equal-weight structure separates it from cap-weighted peers and creates…
AI-assisted drug discovery isn’t just science fiction anymore, especially as biotechnology and biopharma firms embrace the AI age. Undoubtedly, it’s no mystery as to why many wish to be underweight in the…
Recursion Pharmaceuticals (NASDAQ:RXRX) stock is one of those lesser-known mid-cap biotech plays that investors may be interested in buying on weakness, primarily because of its dealings with the great GPU kingpin Nvidia…
Joey Frenette Nvidia’s Strategic AI Vision Nvidia (NASDAQ:NVDA | NVDA Price Prediction) has solidified its position as the backbone of the artificial intelligence (AI) revolution, with its graphics processing units (GPUs) driving the most…
Because Nvidia (NASDAQ:NVDA | NVDA Price Prediction) has become the face of artificial intelligence, investors tend to view it as a proxy for the technology. If you want to buy into AI’s…
Don’t look now, but Cathie Wood of Ark Invest is fresh off an impressive comeback year, with her broader basket of disruptive technology funds posting high double-digit percentage returns. Notably, the flagship…
Investors either love Cathie Wood or hate her. The founder of the Ark Invest family of exchange-traded funds can either be phenomenally successful or a dismal failure. While Wood formed her investment…
